Press Release

Publication of Supplementary Prospectus

Basingstoke, UK and Philadelphia, US – 29 April 2008 – Shire plc (“Shire”) (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that following the publication of the Prospectus by Shire Limited on 16 April 2008 in relation to the introduction of up to 700,000,000 Ordinary Shares of 5 pence each to the Official List, a Supplementary Prospectus is to be made available through publication on Shire’s website: www.shire.com for the purpose of disclosing Shire’s:

• US Food and Drug Administration approval of VYVANSE’s (lisdexamfetamine dimesylate) supplementary New Drug Application for use in the treatment of Attention Deficit Hyperactivity Disorder in adults, which was announced by Shire on 23 April 2008;
• acquisition of arylsufatase–A from Zymenex A/S, which was announced by Shire on 24 April 2008. Arylsufatase–A, currently called METAZYM™, is an enzyme replacement therapy in Phase 1-2 clinical trials and being investigated for the treatment of Metachromatic Leukodystrophy; and
• unaudited financial results for the quarter ended 31 March 2008, which were announced by Shire on 25 April 2008.

The Supplementary Prospectus has been approved by the UK Listing Authority (the "UKLA"). Copies of the Supplementary Prospectus have been submitted to the UKLA and are available for inspection at the UKLA's Document Viewing Facility, which is situated at the Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS.

Copies of the Supplementary Prospectus will also be available for inspection
during usual business hours on Monday to Friday of each week (public holidays
excepted) from the date of publication until admission (expected to be at 8.00
a.m. (London time) on 23 May 2008) at the registered office of Shire Limited being 22 Grenville Street, St. Helier, Jersey, JE4 8PX and at the offices of Slaughter and May, One Bunhill Row, London EC1Y 8YY.